In a situation a judge has called “extraordinary and troubling”, Deloitte’s files on failed construction company Hastie — sought as evidence by shareholders in a class action — have vanished from the accounting giant’s locked ‘litigation room’ and are now in the control of a single partner who refuses to return them.
A multi-million dollar settlement has been reached in a shareholder class action against private training company Ashley Services over its $67 million tumble two years ago.
A case that challenges the test for determining casual employment under the Fair Work Act is a matter of public importance and will be heard by the Full Federal Court, the court’s top judge has said.
Online news publisher Buzzfeed will have to defend an allegation by Labor MP Emma Husar that an article it published implied she’s a “slut”, despite never actually using the word to describe the politician.
Debt collector ACM Group has been hit with a $750,000 fine for engaging in unconscionable conduct by misleading, harassing and coercing two vulnerable customers while chasing unpaid debts.
Johnson & Johnson unit Ethicon is seeking a class closure order in the pelvic mesh class action, as the company prepares to enter mediation.
The Australian Competition and Consumer Commission has lost an appeal of a ruling that dismissed its case over allegedly inadequate disclosures by private health insurer Medibank relating to member benefits.
Generic drug giant Teva has filed a lawsuit seeking to have German pharmaceutical company Boehringer’s patent for an inhalation capsule, which is used to deliver the active drug in its blockbuster Spiriva asthma inhaler, declared invalid.
The law firms that challenged a ruling staying their cases against GetSwift gave the Full Federal Court a chance to guide judges managing competing class actions, but they can’t avoid paying their opponents’ legal costs because the court happened to seize the opportunity.
A judge has denied Sanofi’s bid to block Alphapharm from listing its insulin injector pen on the Pharmaceutical Benefit Scheme, saying Sanofi has not established a strong enough case of infringement to justify granting the injunction.